CalciMedica (CALC) Expected to Release Quarterly Earnings on Wednesday

CalciMedica (NASDAQ:CALC) is projected to announce its resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($1.2750) per share for the quarter.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.97. On average, analysts expect CalciMedica to post ($5.25) EPS for the current fiscal year and ($3.15) EPS for the next fiscal year.

CalciMedica Stock Performance

CALC stock opened at $1.44 on Wednesday. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 1.67. The stock has a 50-day moving average price of $1.70 and a 200-day moving average price of $4.01. The firm has a market cap of $9.84 million, a PE ratio of -0.21 and a beta of 0.84. CalciMedica has a 1-year low of $1.00 and a 1-year high of $36.00.

Wall Street Analysts Forecast Growth

Several research firms have commented on CALC. Weiss Ratings raised shares of CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a report on Wednesday, July 29th. Wall Street Zen downgraded shares of CalciMedica from a “sell” rating to a “strong sell” rating in a report on Saturday, September 12th. UBS Group reissued a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. Finally, Guggenheim started coverage on shares of CalciMedica in a report on Thursday, August 20th. They issued a “buy” rating on the stock. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, CalciMedica currently has a consensus rating of “Hold” and a consensus target price of $50.00.

CalciMedica Company Profile

CalciMedica, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.

CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.